MGX (Metagenomi Therapeutics) Short Interest


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.19
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MGX vs HYPD, ATYR, ACTU: Short Interest Comparison

For the Biotechnology subindustry, Metagenomi Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Metagenomi Therapeutics's Short Interest falls into.


MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19
Price